A randomized, controlled cross-over trial of dermally-applied lavender (lavandula angustifolia) oil as a treatment of agitated behaviour in dementia by O\u27Connor, Daniel W. et al.
O’Connor et al. BMC Complementary and Alternative Medicine 2013, 13:315
http://www.biomedcentral.com/1472-6882/13/315RESEARCH ARTICLE Open AccessA randomized, controlled cross-over trial of
dermally-applied lavender (Lavandula angustifolia)
oil as a treatment of agitated behaviour in
dementia
Daniel W O’Connor*, Barbara Eppingstall, John Taffe and Eva S van der PloegAbstract
Background: Lavender essential oil shows evidence of sedative properties in neurophysiological and animal studies
but clinical trials of its effectiveness as a treatment of agitation in people with dementia have shown mixed results.
Study methods have varied widely, however, making comparisons hazardous. To help remedy previous
methodological shortcomings, we delivered high grade lavender oil in specified amounts to nursing home
residents whose agitated behaviours were recorded objectively.
Methods: 64 nursing home residents with frequent physically agitated behaviours were entered into a randomized,
single-blind cross-over trial of dermally-applied, neurophysiologically active, high purity 30% lavender oil versus an
inactive control oil. A blinded observer counted the presence or absence of target behaviours and rated participants’
predominant affect during each minute for 30 minutes prior to exposure and for 60 minutes afterwards.
Results: Lavender oil did not prove superior to the control oil in reducing the frequency of physically agitated
behaviours or in improving participants’ affect.
Conclusions: Studies of essential oils are constrained by their variable formulations and uncertain pharmacokinetics
and so optimal dosing and delivery regimens remain speculative. Notwithstanding this, topically delivered, high
strength, pure lavender oil had no discernible effect on affect and behaviour in a well-defined clinical sample.
Trial registration: Australian and New Zealand Clinical Trials Registry (ACTRN 12609000569202)
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The fragrant oil extracted from lavender (Lavandula) is
used as a relaxant in many aged care facilities. While
evidence in support of its use is mixed, its potential for
sedative and anticonvulsant activity is clear. After rapid
absorption via skin or respiration [1], lavender and its
principal components, linalool and linalyl acetate, enter the
brain where they act as depressants, inhibiting glutamate
and GABA receptor binding [2,3].
From a behavioural perspective, lavender reduces conflict
between mice; dampens their motor behaviour, and coun-
ters the stimulating effects of caffeine [4,5]. Its sedative* Correspondence: Daniel.OConnor@monash.edu
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reproduction in any medium, provided the orproperties are significant with 3% inspired linalool reducing
spontaneous motor activity to a greater degree than
1 mg/kg of parenteral diazepam [6]. In humans, lavender
has been shown to lower plasma cortisol levels [7,8]; reduce
the need for post-operative analgesia [9], and exert anti-
anxiety effects equivalent to those of lorazepam 0.5 mg
daily [10]. It has no known adverse effects in customary,
and even substantial, doses [11].
In an effort to find alternatives to psychotropic medica-
tions, there have been several controlled trials of lavender
oil as a treatment of agitated behaviours in nursing home
residents with dementia. Two trials had promising results.
In the first, Holmes et al. sprayed a dementia ward with
either 2% lavender oil or water for two hours daily on
alternating days [12]. All 15 participants had severeral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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nose clip rated participants’ behaviours on the Pittsburgh
Agitation Scale, scores were 20% lower when exposed to
lavender compared to water. In the second study, Lin et al.
administered lavender or sunflower oils by vapour for an
hour each night to 70 nursing home residents with marked
dementia and agitation [13]. After the oils were adminis-
tered in random order for three week periods, scores on
the Cohen Mansfield Agitation Inventory (CMAI) fell by
7% with lavender compared to 1% with sunflower oil.
Four other controlled trials were less positive. Snow et al.
pinned sachets infused with lavender, thyme or neutral oils
for several hours daily to the collars of seven dementia unit
residents [14]. Treatments were rotated every two weeks
while nurses completed the CMAI on alternate days. There
were no significant changes in scores with either lavender
or thyme oil. Smallwood et al. randomly allocated 21
severely demented hospital patients to a lavender oil
massage, neutral oil massage or vaporised lavender oil
coupled with conversation [15]. Treatments were adminis-
tered twice weekly at different times of day for unspecified
periods. Videotapes made four times daily revealed no
significant differences in behaviour. Gray and Clair studied
13 confused nursing home residents who were reluctant
to swallow medications [16]. They were randomly rotated
through exposures on four occasions each to lavender oil,
sweet orange oil, tea tree oil and no aroma. Cotton balls
infused with the oils were pinned to subjects’ collars
20 minutes before their medications were dispensed.
Videotapes of residents’ responses to medication adminis-
tration showed no significant differences in behaviour
during any condition. Finally, Fujii et al. found no changes
in blinded behaviour ratings after lavender oil was applied
three times daily over a four week period to the collars of
14 out of 28 long-term patients with dementia [17].
Differences in lavender formulation, delivery methods,
participant numbers, selection criteria, outcome measures
and time frames make it almost impossible to compare
reports [18]. It is not clear, therefore, why lavender has
proved effective in two earlier studies but not in four
others. Such a varied evidence base concerning a safe,
inexpensive and readily implemented treatment makes it
important to conduct further trials using optimal research
methods [18].
Ideally, studies in this field require that: (i) participants
demonstrate one or more behavioral symptom to a spe-
cified degree and frequency; (ii) treatments are deployed
in time frames and settings when the behavioural symptom
is most evident; (iii) behaviours are counted directly to
limit the bias inherent in staff-completed rating scales;
(iv) observers are blinded as much as possible, (v) and
allowance is made for non-specific placebo effects [19]. For
studies involving fragrance, researchers should wear
nose clips or masks to maintain blinding and the controlcondition should involve a similar amount of time and
physical contact with participants [20].
Optimal dosing regimens and formulations have yet to be
established [20]. When lavender oil is diffused via droplets
or nebuliser, as happened in five of the six previous studies,
the amounts inhaled by an individual nursing home
resident are likely to vary according to dispersion rates,
room size, ventilation patterns and the person’s respiratory
capacity. While central nervous system activity might result
from respiratory, olfactory and/or transdermal delivery,
a limited evidence base suggests that topical application
achieves much higher plasma levels of linalool and linalyl
acetate than inhalation (nothing appears to be known
of olfactory delivery) [11]. Known volumes of oil can be
applied to the skin for specified periods to readily access-
ible and relatively absorbent areas [21], leaving residents
free to move about as they please. Treatment will fail, how-
ever, if the quantities applied are too small to be effective,
regardless of mode of administration. When applied
topically, lavender is typically prescribed in Australia as a
2.5% lotion but there is no evidence to support this choice.
Doses should therefore be substantial so that treatment
effects are not missed.
The current study was designed to address these meth-
odological issues by means of a single-blinded, randomised,
controlled cross-over trial of high strength, certified pure
lavender oil with proven neurophysiological activity. It
was administered topically to nursing home residents with
significant, persistent physically agitated behaviours
that were counted by trained observers before and after
application. Physically agitated behaviours were chosen in
preference to physically aggressive and verbally agitated
behaviours because of their higher frequency and greater
ease of measurement. It was hypothesised that lavender
would be associated with a significantly greater reduction
in selected behaviours than a neutral control oil. Since
lavender appears to act as a sedative, its calming effects on
behaviour should be accompanied by an evident improve-
ment in emotional well-being. Measures of positive and
negative affect were therefore added as outcomes.
Methods
Participants
Study participants were recruited from eight specialist
psychogeriatric nursing homes and three private nursing
homes in Melbourne, Australia, between 2009 and 2011.
The following criteria were required for inclusion: (i) a
rating by nursing staff of at least mild dementia on the
Clinical Dementia Rating scale [22]; (ii) a physically agitated
behaviour that occurred at least several times each day in
daylight hours, at times other than during nursing care, to
a degree that required staff intervention; (iii) an assessment
by the nursing staff, visiting medical practitioner and/or
psychiatrist that the behaviour was not due primarily to
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in the facility for at least three months, and (v) consent to
study participation by the next of kin or guardian. Exclu-
sion criteria included: (i) an acute, life-threatening illness;
(ii) a variable psychotropic medication regime, and (iii) a
medical condition that precluded the use of topical oils.
No attempt was made to distinguish one type of dementia
from another in this severely disabled group.
The trial was approved by all relevant committees
including the Monash University Human Research Ethics
Committee. Written consent was obtained from the next
of kin or legal guardians of all participants.
Materials
Four samples of 100% pure lavender oil (Lavandula
angustifolia) were submitted for electrophysiological ana-
lysis to the Department of Pharmacology and Toxicology,
Otago University, New Zealand, using established methods
[3]. A sample sourced from the Ukraine out-performed
others in reducing synaptic activity and membrane excit-
ability in cultured rat embryo pyramidal cells and was
therefore selected for use in this trial (Prof. George Lees,
personal communication). On preliminary testing, 1 ml of
30% lavender in jojoba oil proved to be the maximum
feasible volume and concentration that could be delivered
topically. Jojoba oil, which had no electrophysiological
activity, was used as a control.
Study design
The full protocol of this randomized, placebo-controlled,
single-blind cross-over trial has been described previously
[23]. Participants were allocated randomly by the project
manager using an Excel random number generator to
either a lavender or control study condition with no
pre-set blocking. They were later crossed over to the
other condition. To capture any cumulative effects, each of
the two experimental conditions comprised three exposures
over a one week period with a four-day washout period
between them. Treatments were administered at times
when nursing staff reported that the selected physically
agitated behaviour was most likely to be present, excluding
times of personal nursing care. To minimise confounding
by intercurrent illness and medication changes, the trial
was limited to a two-week period and nursing and medical
staff were asked not to alter participants’ psychotropic
medications if possible.
The lavender and control oils were stored in identical
vials, marked as A or B. Only a single researcher, who
had no other involvement in the study, was aware of the
allocation. A nursing staff member then massaged 1 ml
of either the lavender or control oil into both forearms
for one minute each, giving a total of 2 mls per session.
Since lavender plasma levels peak after 20 minutes, and
are barely detectable after 90 minutes, participants wereobserved for 30 minutes before and 60 minutes after
application [1]. To maintain observer blinding, nurses
applying the oil wore a nose clip and research assistants,
who completed the observations, applied a mixture of
essential oils to their upper lip to disguise lavender’s
fragrance. It was not considered practicable or desirable to
attempt to blind participants, all of whom had marked
cognitive impairment, to the treatment condition.
Measures
A discretely positioned research assistant recorded if the
selected target behaviour was present (one point) or absent
(zero points) during each minute giving a maximum
score of one point per minute of observation. Results
were computed as mean counts over the three 30-minute
observation periods. Inter-rater reliability was high with
an average Kappa of 0.98 over five training sessions. This
time-sampling method has been used successfully in our
previous studies [24].
Observers also used the Philadelphia Geriatric Center
Affect Rating Scale to record the predominant type of affect
(pleasure, contentment, interest, anger, sadness, anxiety/
fear) evident during every minute [25]. The predominant
affect was rated as one and all others were rated zero
giving a maximum score of one point per minute of obser-
vation. Results were averaged as described above. The mean
Kappa for inter-rater reliability was 0.92. For reasons of
brevity, results for pleasure, contentment and interest
are categorized here as positive affects and those for anger,
sadness and anxiety/fear as negative affects.
Other measures included the Mini-Mental State Examin-
ation (MMSE) and the Cohen-Mansfield Agitation Inven-
tory (CMAI) [26,27]. To identify a suitable behaviour for
use as an outcome measure, the CMAI was completed
at baseline by nursing staff who rated physically agitated
behaviours (e.g. pacing) on a seven-point scale ranging
from “occurs never” to “occurs several times an hour” in
the previous fortnight.
Analysis
Sample size was calculated with respect to the primary
outcome measure of physically agitated behaviour for a
two-sided hypothesis test with a Type I error rate of 0.05
and power set at 90%, based on data from an earlier
repeated measures study of simulated family presence
versus music therapy in a similar population and setting
[24]. In that study, simulated family presence had an effect
size of 0.45 relative to the control condition. However,
given the mixed evidence supporting lavender, it seemed
prudent to apply the smaller effect size of 0.32 for music
therapy. It was estimated that 77 participants might be
required to detect a difference of this magnitude. At the
same time, there were 18 data points for every participant
(6 applications x 3 summary behaviour and affect counts
Assessed for eligibility (n= 440) 
Excluded (n=374)
Inclusion criteria not met 
(n= 361)
Died (n=10)
Relocated (n=2)
Analysed (n=37)
Refused (n=1)
Allocated to lavender first (n=38) 
Received lavender (n=38) 
Died (n=1)
Allocated to placebo first (n=28) 
Received placebo (n=28) 
Analysed (n=27)
Allocation
Analysis
Follow-Up
Randomized (n=66)
Enrollment
Figure 1 Study Flow Chart.
Table 1 Mean (SD) behaviour and affect scores before
and after exposure to lavender and control oils
Behaviour Affect
Positive Negative
Pre- exposure
Lavender 16.1 (10.6) 7.2 (10.2) 0.9 (3.5)
Control 16.9 (10.0) 6.7 (9.7) 1.2 (4.5)
First 30 minutes post-exposure
Lavender 14.5 (10.8) 7.0 (10.1) 0.9 (3.9)
Control 16.0 (10.4) 6.4 (9.9) 1.0 (3.9)
Second 30 minutes post-exposure
Lavender 14.4 (10.6) 6.7 (10.2) 0.7 (3.9)
Control 15.5 (10.7) 6.3 (9.6) 0.9 (3.8)
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power for only a limited number of analyses.
The behaviour and affect scores were over-dispersed
relative to Poisson expectations and were therefore mod-
elled using random effects negative binomial regression,
taking account of participants’ age, gender and dementia
severity. The results of the analyses are shown as mean
scores and incidence rate ratios for completed cases.
Ratios over one signify an increase in a mean value, and
ratios below one signify a decrease in that value, with
respect to a reference condition. Ratios are displayed for
treatment (lavender versus the control reference condition),
time (post-exposure versus the pre-exposure reference
condition) and treatment-time interaction.
Results
Figure 1 shows the processes of participant selection,
enrolment and follow-up. Finding 66 people suitable for
randomization entailed screening 440 residents, most of
whom failed to demonstrate sufficient behavioural dis-
turbance. Once the trial began, all but two participants
completed both study conditions.
Most participants were female (59%); very old (mean age
77.6 years, S.D. 9.4); markedly cognitively impaired (mean
MMSE score 6.1, S.D. 7.0), and physically agitated (mean
CMAI score 40.3, S.D. 18.8). The behaviours selected forobservation (with numbers) included pacing (55), repetitive
mannerisms (5), general restlessness (2), disrobing (1) and
intrusiveness (1).
For reasons of clarity, raw results are listed in Table 1
and shown graphically in Figures 2a and 2b. Findings of
the binomial regression analyses are presented in Table 2.
Table 1 and Figure 2a show that agitated behaviour
counts were lower in the lavender condition than in
the control condition. While this difference approached
statistical significance (p = 0.057), the lower counts were
Behaviour score
Positive affect score
b
a
Figure 2 Mean scores before and after exposure to lavender and control oils. (a) Behaviour. (b) Positive Affect.
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a true treatment effect. Similarly, behavior counts fell with
time to a statistically significant degree but this occurred
regardless of condition. There were no significant treat-
ment-time interactions.
Results were similar for affect ratings (Table 1, Figure 2b).
Counts of positive affect were higher in all lavenderTable 2 Incidence Rate Ratios (IRR) with 95% confidence inte
interaction on behaviour and affect scores after taking accou
Behaviou
IRR
Treatment Lavender compared to control 0.884 (0.778-1.004)
Time First 30 minutes post-exposure
compared to pre- exposure
0.899 (0.793-1.020)
Second 30 minutes post-exposure
compared to pre- exposure
0.858 (0.755-0.974)
Treatment- time
interactions
Lavender x first 30 min.
post-exposure
0.961 (0.798-1.157)
Lavender x second 30 min
post-exposure
1.045 (0.869-1.259)than control periods but not to significantly different
degree. Counts then fell with time, regardless of treat-
ment condition, but this difference was also not
significant.
No dermatological or other possible or probable adverse
effects were noted as a result of exposure to either the
lavender or control oils.rvals for effects of treatment, time and treatment-time
nt of age, gender and dementia severity
r Affect
Positive Negative
p value IRR p value IRR p value
0.057 1.072 (0.848-1.355) 0.56 0.891 (0.504-1.573) 0.690
0.097 0.900 (0.706-1.147) 0.393 0.960 (0.550-1.675) 0.887
0.018 0.865 (0.678-1.106) 0.248 0.641 (0.348-1.179) 0.153
0.672 1.020 (0.726-1.433) 0.910 0.848 (0.371-1.938) 0.696
0.636 0.954 (0.675-1.348) 0.790 0.687 (0.269-1.750) 0.431
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Counts of agitated behaviours were lower during exposure
to lavender than to the control oil but this occurred before
and after exposure. The observed differences were most
probably due to chance. Counts of agitated behaviours
also declined over the 90-minute observation period, irre-
spective of experimental condition, consistent with a spon-
taneous remission in symptom severity. Treatment was
delivered at the time of day when agitated behaviours were
expected to peak to maximise the chances of identifying
any benefit. Since symptoms wax and wane over the
24-hour period, behaviours were likely to remit regardless
of intervention, representing a simple regression to the
mean rather than a genuine therapeutic effect.
In devising the protocol, we had sought to avoid the
methodological pitfalls identified in previous systematic
reviews of treatments of the behavioural and psychological
symptoms of dementia [19,28]. Participants had proven,
frequent behavioural symptoms; high strength lavender
oil with demonstrable neurophysiological activity was
administered in a uniform fashion to nursing home resi-
dents who were reasonably typical of those with marked
behavioural disturbances, and behaviour and affect were
measured reliably over a plausible time frame by raters
who were blinded to treatment condition.
To ensure statistical power, we sought 77 subjects based
on data from an earlier controlled trial of a psychosocial
intervention using identical methods in a similar clinical
sample. We succeeded in recruiting and retaining only 64
people, despite doubling the study period from one to two
years. It seems very unlikely, however, that our negative
results are due to inadequate power as there is no sugges-
tion in the raw data of any improvement in behaviour or
affect during exposure to lavender relative to the control
oil based on a limited number of analyses of a very large
number of data points.
The most significant limitation to research of essential
oils concerns product variability and the limited knowledge
base of lavender’s pharmacological properties. There are
very few studies of its absorption, metabolism and central
nervous system availability in animals and healthy humans,
let alone frail older people with dementia. Lavender appears
to be well absorbed and to have sedative and anticonvulsant
potential but information is otherwise limited with the
result that dosing strategies are based largely on traditional
practice. We settled on a topical dose of 1 ml 30% certified
pure lavender oil applied to each forearm only because
a higher strength was so viscous that application became
impracticable. This was still much higher than the doses
delivered by vapour in most previous studies. Future
researchers should consider measuring plasma levels of
linalool and linalyl acetate as a check on absorption.
The current lack of information also makes it difficult
to understand why two studies have returned positiveresults while five others, including the present one, have
not. Without a consistent proprietary formulation and
sound pharmacokinetic data, of the kind now reported
routinely for new pharmaceutical products, there may be
little value in further clinical trials.
Conclusion
Studies of essential oils are constrained by their variable
formulations and uncertain pharmacokinetics and so
optimal dosing and delivery regimens remain speculative.
Notwithstanding this, topically delivered, high strength,
pure lavender oil had no discernible effect on affect and
behaviour in a well-defined clinical sample.
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